SCHEDULE: Sinclair Challenges Scripps' Poison Pill, Pushes for Merger

Sinclair, Inc. has amended its Schedule 13D filing to express strong disagreement with The E.W. Scripps Company's adoption of a shareholder rights plan, reiterating its belief in a strategic business combination.

Summary

• Sinclair, Inc. filed Amendment No. 3 to its Schedule 13D regarding its beneficial ownership in The E.W. Scripps Company.
• The amendment primarily addresses The E.W. Scripps Company's adoption of a shareholder rights plan, commonly known as a 'poison pill', on November 26, 2025.
• Sinclair believes the strategic and financial rationale of a potential business combination with The E.W. Scripps Company is indisputable.
• Sinclair views the poison pill as a measure that limits liquidity opportunities for public shareholders, especially given The E.W. Scripps Company's family control.
• Sinclair submitted a proposal to The E.W. Scripps Company, building upon prior constructive discussions, and intends to continue engagement for a mutually agreeable transaction.
• Sinclair beneficially owns 7,625,401 shares of Class A Common Stock, representing 9.9% of the class.
• The percentage of ownership is calculated based on 76,869,408 shares of Class A Common Stock outstanding as of September 30, 2025.

Sentiment

Score: 3

Explanation: The filing indicates a significant hurdle (poison pill) to Sinclair's stated objective of a business combination, suggesting a negative development for Sinclair's immediate strategic goals, despite Sinclair's continued optimism.

Positives

• Sinclair believes a potential business combination with The E.W. Scripps Company has 'indisputable' strategic and financial rationale.
• Sinclair is actively pursuing a mutually agreeable transaction that could deliver significant benefits to The E.W. Scripps Company's shareholders and local communities.

Negatives

• The E.W. Scripps Company adopted a shareholder rights plan (poison pill), which Sinclair believes limits liquidity opportunities for public shareholders.

Risks

• The adoption of a 'poison pill' by The E.W. Scripps Company could hinder Sinclair's efforts to pursue a business combination.
• Family control of The E.W. Scripps Company may influence decisions regarding potential transactions, potentially limiting public shareholder liquidity.

Future Outlook

Sinclair intends to continue engaging with The E.W. Scripps Company to reach a mutually agreeable transaction that will deliver significant benefits to shareholders and local communities.

Management Comments

• "The strategic and financial rationale of a potential business combination with the Issuer is indisputable."
• "Given the family control of the Issuer, the only effect of adopting a poison pill is to limit liquidity opportunities available for public shareholders of the Issuer."
• "The Reporting Person intends to continue to engage with the Issuer in an effort to reach a mutually agreeable transaction that will deliver significant benefits to the Issuer's shareholders and local communities."

Industry Context

This filing highlights ongoing consolidation efforts and strategic maneuvers within the media and broadcasting industry, where companies like Sinclair often seek to expand their market presence through acquisitions. The use of a 'poison pill' by Scripps indicates a defensive posture against potential hostile takeovers, a common theme in industries undergoing consolidation.

Comparison to Industry Standards

• Shareholder rights plans (poison pills) are a common defensive tactic employed by target companies to deter unsolicited takeover bids, similar to those used by companies like Sprint against SoftBank or Allergan against Valeant in past M&A battles.
• Sinclair's continued pursuit of a business combination, despite defensive measures, is typical of strategic acquirers who see significant synergies and value in a target, akin to Comcast's persistent pursuit of Sky.

Corporate Governance

Stakeholder Impact

• Shareholders (Scripps): The poison pill limits liquidity opportunities, potentially impacting their ability to realize value from a takeover bid. A successful business combination could offer significant benefits.
• Shareholders (Sinclair): The pursuit of a business combination, if successful, could lead to strategic growth and value creation. The poison pill presents a challenge to this objective.
• Local Communities: A mutually agreeable transaction is stated to deliver significant benefits to local communities, implying potential improvements or stability in local broadcasting services.

Next Steps

• Sinclair, Inc. intends to continue engaging with The E.W. Scripps Company.
• Sinclair aims to reach a mutually agreeable transaction.

Key Dates

Recommendation

The E.W. Scripps Company's adoption of a 'poison pill' creates a significant barrier to Sinclair's stated interest in a business combination, introducing uncertainty regarding the likelihood and terms of any future transaction. While Sinclair remains committed to pursuing a deal, the defensive measure suggests a potentially prolonged or difficult negotiation process. For investors, this situation warrants a 'hold' recommendation to observe how the corporate governance battle unfolds and whether a mutually agreeable transaction can be reached, rather than making a definitive buy or sell decision based on the current contentious environment.

Keywords

Sinclair, E.W. Scripps, Schedule 13D, poison pill, shareholder rights plan, business combination, merger, media, broadcasting, common stock, beneficial ownership